LFCR Stock - Lifecore Biomedical, Inc.
Unlock GoAI Insights for LFCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $128.87M | $128.26M | $103.27M | $111.27M | $100.87M |
| Gross Profit | $40.30M | $41.85M | $27.98M | $39.07M | $38.94M |
| Gross Margin | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% |
| Operating Income | $-17,245,000 | $-8,844,000 | $-21,796,000 | $-11,791,000 | $-8,823,000 |
| Net Income | $-38,717,000 | $12.01M | $-99,563,000 | $-116,715,000 | $-32,294,000 |
| Net Margin | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% |
| EPS | $-1.27 | $0.39 | $-3.32 | $-3.97 | $-1.12 |
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 4th 2025 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| May 21st 2025 | William Blair | Initiation | Outperform | - |
| September 5th 2024 | Craig Hallum | Initiation | Buy | $8 |
| August 28th 2024 | Barrington Research | Downgrade | Market Perform | - |
| March 20th 2023 | Stephens | Downgrade | Equal Weight | $2← $11 |
Earnings History & Surprises
LFCREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 1, 2026 | — | — | — | — |
Q1 2026 | Jan 1, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.30 | $-0.29 | +3.3% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q2 2025 | Apr 3, 2025 | $-0.14 | $-0.19 | -35.7% | ✗ MISS |
Q1 2025 | Jan 2, 2025 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2024 | Aug 26, 2024 | $-0.12 | $-0.15 | -25.0% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.12 | $-0.41 | -241.7% | ✗ MISS |
Q2 2024 | May 22, 2024 | $-0.23 | $0.43 | +285.7% | ✓ BEAT |
Q4 2023 | Dec 29, 2023 | $-0.23 | $0.39 | +269.7% | ✓ BEAT |
Q3 2023 | Aug 31, 2023 | $-0.07 | $-0.89 | -1171.4% | ✗ MISS |
Q2 2023 | Jun 1, 2023 | $-0.13 | $-0.22 | -69.2% | ✗ MISS |
Q2 2023 | May 16, 2023 | $-0.13 | $-0.22 | -69.2% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.04 | $-0.24 | -500.0% | ✗ MISS |
Q4 2022 | Oct 6, 2022 | $-0.13 | $-0.32 | -146.2% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.01 | $-0.01 | -25.0% | ✗ MISS |
Q2 2022 | Apr 5, 2022 | $-0.01 | $-0.08 | -1500.0% | ✗ MISS |
Q1 2022 | Jan 5, 2022 | $0.02 | $0.05 | +225.1% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | $-0.12 | $-0.23 | -91.7% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $0.01 | $0.07 | +975.3% | ✓ BEAT |
Latest News
Lifecore Biomedical To Join Nasdaq Biotechnology Index Effective Before Market Open December 22, 2025
📈 PositiveLifecore Biomedical shares are trading higher after the company announced that it has signed a CDMO master services agreement with a global pharmaceutical customer.
📈 PositiveLifecore Biomedical Lands Major Global Pharma Deal to Make Injectable Drug in the US
📈 PositiveLifecore Biomedical Affirms FY2026 Sales Guidance of $74.000M-$76.000M vs $131.882M Est
📉 NegativeLifecore Biomedical Q1 EPS $(0.29) Beats $(0.30) Estimate, Sales $31.109M Beat $26.471M Estimate
📈 PositiveLifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug
📈 PositiveLifecore Biomedical And PolyPeptide Form Strategic Collaboration To Provide Fully Integrated Peptide Manufacturing And Development Capabilities For US Customers
📈 PositiveLifecore Files Preliminary Prospectus To Offer Up To $150M In Common Stock And Warrants
➖ NeutralKeybanc Initiates Coverage On Lifecore Biomedical with Sector Weight Rating
➖ NeutralFrequently Asked Questions about LFCR
What is LFCR's current stock price?
What is the analyst price target for LFCR?
What sector is Lifecore Biomedical, Inc. in?
What is LFCR's market cap?
Does LFCR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LFCR for comparison